Dr. Robert C. Alexander, M.D.
Psychiatry (Psychiatry Physician)
At a glance
- In the NPI registry since
- 2012
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2012Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Psychiatry Physician primary
MA license 55341 · PA license MD044532L
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Payments from drug and device companies
In 2025, 2 companies reported 8 payments worth $6,755 in total to this clinician.
| Boehringer Ingelheim International GmbH | $6,250 |
|---|---|
| Alkermes, Inc. | $505 |
| Consulting Fee | $6,755 |
|---|
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Boehringer Ingelheim International GmbH Feb 5, 2025 | Consulting Fee | $1,500 |
| Boehringer Ingelheim International GmbH Feb 5, 2025 | Consulting Fee | $1,500 |
| Boehringer Ingelheim International GmbH Dec 10, 2025 | Consulting Fee | $1,250 |
| Alkermes, Inc. Jun 9, 2025 | Consulting Fee | $505 |
| Boehringer Ingelheim International GmbH May 23, 2025 | Consulting Fee | $500 |
| Boehringer Ingelheim International GmbH Jun 12, 2025 | Consulting Fee | $500 |
| Boehringer Ingelheim International GmbH Jul 16, 2025 | Consulting Fee | $500 |
| Boehringer Ingelheim International GmbH Sep 10, 2025 | Consulting Fee | $500 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $79,890 in research payments for these studies, mostly to the institutions running them.
- A single-center, adaptive, repeated dose, phase i study to investigate the pharmacodynamics of RO7269162 following oral administration in presymptomatic PSEN1 E280A mutation carriers
F. Hoffmann-la Roche AG
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.